New and Emerging Treatments for Pulmonary Fibrosis
Wednesday, January 21, 7:00 am EST, 2026
Didactic Presenter:
Barry Shea, MD
Case Discussion Facilitator:
Robert Hallowell, MD
Related Document(s):
- About
- Partner Centers
- People
- Project ECHO for ILD
- 2022-2023 Curriculum
- Idiopathic Pulmonary Fibrosis: A Diagnostic Approach
- Shifting Paradigms of IPF Pathogenesis
- Treatments for Idiopathic Pulmonary Fibrosis
- Overview of Autoimmune ILD
- Scleroderma-Associated ILD: Clinical Manifestations and Diagnosis
- Idiopathic Pulmonary Fibrosis: Natural History and Survival
- Myositis-Associated ILD: Clinical Manifestations and Diagnosis
- Lung Biopsy in the Diagnosis of Fibrotic ILD
- Sarcoidosis: Overview, Diagnosis and Monitoring
- Rethinking Classification Criteria for Connective Tissue Diseases
- Post-acute Sequelae of COVID-19 (PASC)
- Acute Exacerbations of ILD
- Scleroderma-Associated ILD: Treatment Approaches and Challenges
- Myositis-Associated ILD: Treatment Approaches and Challenges
- Pulmonary Hypertension Associated with ILD
- More Than Meds: Nonpharmacologic Treatments for ILD
- Hypersensitivity Pneumonitis: Approach and Challenges
- Lung Transplant for ILD: When to Refer and What to Expect
- Sarcoidosis: Beyond First Line Therapy
- Genetics and the Development of Pulmonary Fibrosis
- Hypersensitivity Pneumonitis: Treatment Approach and Challenges
- HRCT Patterns and Pitfalls: Approach to Fibrotic Lung Disease
- Common Comorbidities of ILD
- Quality of Life and ILD: Palliative Care Along the Trajectory of Illness
- 2024-2025 Curriculum
- Rheumatoid Arthritis-Associated ILD
- Shifting Paradigms of IPF Pathogenesis
- HRCT Patterns and Pitfalls: Approach to Fibrotic Lung Disease
- Myositis-Associated ILD: Clinical Manifestations and Diagnosis
- Emerging Treatments for Pulmonary Fibrosis and Active Clinical Trials
- Lung Cancer in Patients with ILD: Diagnostic and Management Considerations
- Rethinking Classification Criteria for Connective Tissue Diseases
- A Guide to Immunosuppression
- Lung Biopsy in the Diagnosis of ILD
- Hypersensitivity Pneumonitis: Diagnostic Approach and Challenges
- ANCA-associated ILD
- Acute Exacerbations of ILD
- Hypersensitivity Pneumonitis: Update on Treatment Approaches
- Pulmonary Complications of Immunotherapy
- Long COVID
- Scleroderma-Associated ILD
- Pulmonary Hypertension Associated with ILD: Diagnosis and Management
- Occupational Lung Disease
- Myositis-Associated ILD: Treatment Approaches and Challenges
- Lung Transplant for ILD: When to Refer and What to Expect
- Obliterative Bronchiolitis
- Sarcoidosis: Conventional and Evolving Treatments
- 2026 Curriculum
- Treatments for Pulmonary Fibrosis and Active Clinical Trials
- Rheumatoid Arthritis-Associated ILD
- ANCA-associated ILD
- Hypersensitivity Pneumonitis: Diagnostic Approach and Challenges
- Lung Biopsy in the Diagnosis of ILD
- Rethinking Classification Criteria for Connective Tissue Diseases
- HRCT Patterns and Pitfalls: Approach to Fibrotic Lung Disease
- Myositis-Associated ILD: Clinical Manifestations and Diagnosis
- HRCT Patterns and Pitfalls: Approach to Fibrotic Lung Disease
- Acute Exacerbations of ILD
- Hypersensitivity Pneumonitis: Update on Diagnostic and Treatment Challenges
- More Than Meds: Nonpharmacologic Treatments for ILD
- Pulmonary Complications of Immunotherapy
- Rheumatoid Arthritis-Associated ILD: Update on Treatment Approaches
- Scleroderma-Associated ILD: Treatment Approaches and Challenges
- Myositis-Associated ILD: Treatment Approaches and Challenges
- Extrapulmonary Sarcoidosis
- Pulmonary Hypertension Associated with ILD: Diagnosis and Management
- Lung Transplant for ILD: When to Refer and What to Expect
- Bronchiolitis: A Clinical Approach
- A Guide to Starting and Monitoring Immunosuppression
- Quality of Life and ILD: The Role of Palliative Care
- Project ECHO for ILD
- Registration
- 2022-2023 Curriculum
- Virtual Meetings
- Air Filtration
- Air Pollution and Interstitial Lung Disease
- Airway Clearance
- Airway Clearance and Methods of Cough Reduction
- Anesthesia for People With Interstitial Lung Disease
- Art Therapy in Chronic Illness
- Cough in ILD: Its Causes and Management
- Eight Active Ingredients of Tai Chi
- Fuel for the Fight: The Role of Nutrition in Managing ILD
- Gastroesophageal Reflux Disease (GERD) and ILD
- Hypersensitivity Pneumonitis
- Immunomodulatory Agents in the Treatment of ILD
- Implementing Energy Conservation Strategies
- Interstitial Lung Disease Therapies
- Interstitial Lung Disease: The Journey to Diagnosis and Treatment
- Living Better with ILD
- Lung Transplant: Eligibility and Evaluation
- Managing Fatigue: An Educational Guide to Energy Conservation
- Medical Management of ILD Symptoms
- Monthly Oxygen Therapy Series: Is It Time to Use Oxygen?
- Monthly Oxygen Therapy Series: Portable Oxygen Concentrators and Travel
- Monthly Palliative Care Series: Palliative Care and QoL in ILD
- Nutritional Considerations for ILD
- Oxygen Usage
- Pranayama: The Art and Science of Slow Breathing
- Pulmonary Hypertension: Diagnosis and Management
- Sarcoidosis: Is There Better Treatment?
- The Lived Experience Series: Financial and Tax Planning
- The Role of Ablation for Lung Cancer Treatment in ILD
- Traditional Pulmonary Rehab vs Pulmonary Rehab for ILD
- Traveling with Oxygen
- Understanding Autoimmune-Related ILD
- Unsubscribe from our Mailing Lists
- Updates on Clinical Research for IPF and Other Forms of ILD (2023)
- Updates on Clinical Research for IPF and Other Forms of ILD
- What Patients With ILD Need to Know About Anesthesia
- What is Dialectical Behavior Therapy?
- Resources
- Aspirational Patient Journey
- Basics of ILDs
- Basics of IPF
- Blog
- Genetics of Familial Idiopathic Interstitial Pneumonia
- IPF Patient Journey
- IPF and PF-ILD Clinical Trials
- Monitoring Disease Progression in Idiopathic Pulmonary Fibrosis
- Patient Symposium
- Peer To Peer Support
- Phase IV IPF Clinical Trials
- Pulmonary Function Testing
- Starting Oxygen Therapy
- Support Groups
- Webinars
- Clinical Trials
